Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Giant Cell Arteritis
NCT01450137Phase 2Completed
- Sponsor
- Insel Gruppe
- Start
- Sep 2011
- Primary completion
- Dec 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Tocilizumab + Glucocorticoids with Placebo + Glucocorticoids (2 arms). Primary endpoint: Number of Patients That Have Achieved Complete Remission of Disease at 12 weeks. Started Sep 2011; status: completed.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT01450137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01450137.